We use essential cookies to make our site work. With your consent, we may also use non-essential cookies to improve user experience and analyze website traffic. By clicking "Accept," you agree to our website's cookie use as described in our Privacy Policy.
Oops! Something went wrong while submitting the form.
Pioneering a new class of treatments for neuro-visual disorders.
Around 15 million Americans suffer from vision loss caused by deficiencies in the brain, instead of any structural issues with the eyes. Traditional therapeutic modalities are unable to properly target and treat these deficits, leaving a significant unmet need.
Scroll to learn more
By harnessing the latest in digital technology, we're creating an entirely new category of medicines to address these conditions. We develop software products that generate therapeutic visual stimuli and deliver them to the patient through a virtual reality headset, using the eyes to stimulate the brain. The success of our amblyopia therapeutic provides proof-of-concept for our broader platform.
To achieve our mission, we've brought together a world-class team with deep experience and a true passion for helping patients.
Brion Raymond
CBO
Former CCO at Clearside Biomedical
Former Director at Genentech
Drew Mowery
VP of Commercial Strategy
Former Sr Director at Ultragenyx Pharmaceutical
Former Director at bluebird bio and Genentech
Hank Wu
COO
Former VP of Digital at Evelo Biosciences
Former Director at Biogen
Richard Plank
National Sales Director
Former Area Director at Sight Sciences
Former Senior District Manager at Alcon
Scott Xiao
Co-Founder and CEO
MIT TR Innovators Under 35
Forbes 30 Under 30
Shelley Hancock
Sr Director, Medical Affairs
Former Sr Director, Medical & Professional Affairs at Clearside Biomedical
Stephanie Roberts
Head of Market Access
Former Sr Director, National Accounts at Akili
Former National Accounts Director at Otsuka and Acorda
Sunny Atwal
VP of Engineering
Former VP of Technology at Moth+Flame
Former SVP of Technology at Littlstar
Board of Directors
We're proud to have the support of an exceptional Board of Directors, with leaders from across healthcare, tech, and entertainment.
Casey Tansey
General Partner at USVP
Former CEO at Epicor Medical, Heartport
Dean Travers
Co-Founder
Thiel Fellow
Forbes 30 Under 30
Mark Jacobstein
Executive Business Advisor at Immunai
Former CUEO at Guardant Health
Robert Langer, ScD
Institute Professor at MIT
Co-Founder of Moderna
Most cited engineer in history
Scott Xiao
CEO
MIT TR Innovators Under 35
Forbes 30 Under 30
William Dai
Founding Managing Partner at ShangBay Capital
Former CFO at Boston Scientific China
Investors
We're grateful to have the backing of several top-tier investment firms who share our vision for the future.
Platform Scientific Advisors
We're thrilled to have a group of renowned clinicians and scientists guiding the development of our platform.
Peter J. McDonnell, MD
Director, Professor Of Ophthalmology
The Wilmer Eye Institute
Marguerite McDonald,MD, FACS
Director, Professor Of Ophthalmology
New York University Langone Medical Center
Peter Bex, PhD
Chair Of Psychology
Northeastern University
Krystel Huxlin, PhD
Professor Of Ophthalmology
University of Rochester
Eric Singman, MD
Professor Of Ophthalmology
University of Maryland
The following Luminopia products, either alone or in combination with other products, are protected by one or more of the identified patents. The absence of a product name or patent number associated with any listed product does not constitute a waiver of Luminopia’s intellectual property rights concerning that product. This page is intended to serve as notice under 35 U.S.C. § 287(a).
Product
U.S. Patents, Pending U. S. Applications, and Foreign Counterparts
.png)
.png)
.png)
.png)
